Back to List View Graph View

Adalimumab

Adalimumab is a therapeutic monoclonal antibody used as an anti-inflammatory biologic agent.

Where the papers sit

20 papers from the last 6 months study adalimumab directly · updated from PubMed 12 Nov 2026

  • Adalimumab Therapeutic Optimization

    Resistance in rheumatoid arthritis is being linked to synovial short-lived plasma cells and the MIF-CD74 axis, partly independent of TNF-α. Other work examines M1 macrophage reprogramming to reduce Th1/Th17 responses in inflammatory eye disease. Sustained delivery is pursued through cell-based antibody release and polyelectrolyte nanocomplexes that slow synovial clearance. Upadacitinib comparisons, methotrexate effects on immunogenicity, and Fab stability address durability and product performance.

    7 papers · 35%

  • Advanced Therapy in Inflammatory Bowel Disease

    Inflammatory bowel disease care is moving toward normalized biosimilar use, comparative selection among infliximab, adalimumab, and ustekinumab, and closer attention to treatment persistence. Population pharmacokinetic models support individualized dosing, while studies examine heart-failure risk and outcomes in pediatric disease. Persistence and remission remain central endpoints in Crohn’s disease and broader IBD cohorts. Adalimumab does not consistently remodel intestinal monocyte and macrophage metabolism after remission, leaving biological response mechanisms unresolved.

    7 papers · 35%

  • Psoriasis and Hidradenitis Treatment

    Adalimumab use is expanding across psoriasis and hidradenitis suppurativa, including biosimilar treatment and first-line care. Clinical work emphasizes efficacy, safety, and durability, with predictors of sustained response being sought in hidradenitis. Pediatric psoriasis experience extends the evidence base beyond adults. Granulomatous lobular mastitis provides a related real-world application, but the shared focus remains biologic treatment of inflammatory skin disease.

    4 papers · 20%

  • Biosimilar Switching and Costs

    Adalimumab biosimilar adoption is being assessed through both economic counterfactuals and real-world switching behavior. Analyses estimate savings against reference-biologic spending while tracking switches and switch-backs in the United States. The recurring question is whether lower acquisition costs translate into durable use without disruptive treatment changes. Evidence remains observational and does not yet establish why patients switch back or which strategies best sustain biosimilar uptake.

    2 papers · 10%

NEW DIRECTION

Adalimumab is repurposed as a continuously produced payload of an implantable cell-based biologics factory

The once-yearly cell-based antibody-delivery study 42826187Oct treats adalimumab not as a repeatedly injected therapeutic, but as one of several antibodies manufactured in vivo by an encapsulated allogeneic cell chassis. The platform sustained antibody delivery after a single administration, giving adalimumab a new role as a product of an implantable biologics-production system rather than a conventionally administered drug.

NEW DIRECTION

Adalimumab is reformulated as a synovium-retaining nanocomplex for prolonged local joint exposure

The ex vivo osteoarthritis joint-delivery study 42300546Jun uses adalimumab as cargo in a cationic polyelectrolyte nanocomplex designed to interact with the negatively charged synovial matrix. Instead of relying on freely diffusible intra-articular antibody, the formulation immobilized adalimumab in superficial synovial tissue, reduced its trans-synovial flux, and retained target-binding activity, establishing a distinct local drug-delivery role.

Papers

The 20 papers from the last 6 months that study adalimumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Adalimumab Therapeutic Optimization (7)
  1. Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies. Science advances · 2 Oct 2026 PMID 42826187
  2. Methotrexate's effect on cells and adalimumab immunogenicity in axial spondyloarthritis: A mathematical study. PLoS computational biology · 21 Sept 2026 PMID 42766629
  3. Synovial short-lived plasma cells mediate adalimumab resistance in rheumatoid arthritis via MIF-CD74 axis-driven, partially TNF-α-independent inflammation. Journal of autoimmunity · 4 Sept 2026 PMID 42696910
  4. Position-dependent effects of loop proline residues on Fab stability and aggregation. Biochemical and biophysical research communications · 21 Jul 2026 PMID 42480179
  5. Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. RMD open · 24 Jun 2026 PMID 42342288
  6. Adalimumab-polyelectrolyte nanocomplexes decelerate synovial drug clearance ex vivo. Nanoscale · 16 Jun 2026 PMID 42300546
  7. Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt-Koyanagi-Harada Syndrome. Investigative ophthalmology & visual science · 2 Jun 2026 PMID 42227805
Advanced Therapy in Inflammatory Bowel Disease (7)
  1. No detectable remission-specific remodeling of intestinal monocyte and macrophage metabolic transcriptional programs after adalimumab in Crohn's disease: A patient-level reanalysis of a longitudinal single-cell atlas. PloS one · 11 Nov 2026 PMID 43013487
  2. Treatment patterns and determinants of persistence with advanced therapies in adults with newly diagnosed Crohn's disease: an interim analysis of an inception cohort registry study (iCREST-CD). Journal of Crohn's & colitis · 7 Nov 2026 PMID 42998010
  3. Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization. Revista espanola de enfermedades digestivas · 26 Oct 2026 PMID 42929266
  4. External validation of population pharmacokinetic models of adalimumab in adult patients with inflammatory bowel disease: towards model-informed precision dosing. Journal of pharmacokinetics and pharmacodynamics · 29 Jul 2026 PMID 42527726
  5. Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183
  6. Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database. Proceedings (Baylor University. Medical Center) · 10 Jun 2026 PMID 42269048
  7. The Longer-Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population-Based Study. Pharmacoepidemiology and drug safety · 20 May 2026 PMID 42157439
Psoriasis and Hidradenitis Treatment (4)
  1. Efficacy and safety of adalimumab as first-line therapy for treatment-naïve granulomatous lobular mastitis: an exploratory real-world study with propensity score-matching analysis. Clinical rheumatology · 26 Sept 2026 PMID 42799973
  2. Predictors of adalimumab durability in hidradenitis suppurativa: a multicenter cohort study. The Journal of dermatological treatment · 20 Aug 2026 PMID 42619449
  3. Biologic therapies in pediatric psoriasis: A single-center experience. Archivos argentinos de pediatria · 30 Jun 2026 PMID 42377011
  4. Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: A Clinical Experience. Saudi medical journal · 15 Jun 2026 PMID 42293717
Biosimilar Switching and Costs (2)
  1. Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
  2. Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025). Journal of managed care & specialty pharmacy · 24 Jun 2026 PMID 42341073

By study type

Clinical trials (1)
  1. Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. RMD open · 24 Jun 2026 PMID 42342288
Observational studies and case reports (10)
  1. No detectable remission-specific remodeling of intestinal monocyte and macrophage metabolic transcriptional programs after adalimumab in Crohn's disease: A patient-level reanalysis of a longitudinal single-cell atlas. PloS one · 11 Nov 2026 PMID 43013487
  2. Treatment patterns and determinants of persistence with advanced therapies in adults with newly diagnosed Crohn's disease: an interim analysis of an inception cohort registry study (iCREST-CD). Journal of Crohn's & colitis · 7 Nov 2026 PMID 42998010
  3. Synovial short-lived plasma cells mediate adalimumab resistance in rheumatoid arthritis via MIF-CD74 axis-driven, partially TNF-α-independent inflammation. Journal of autoimmunity · 4 Sept 2026 PMID 42696910
  4. Predictors of adalimumab durability in hidradenitis suppurativa: a multicenter cohort study. The Journal of dermatological treatment · 20 Aug 2026 PMID 42619449
  5. External validation of population pharmacokinetic models of adalimumab in adult patients with inflammatory bowel disease: towards model-informed precision dosing. Journal of pharmacokinetics and pharmacodynamics · 29 Jul 2026 PMID 42527726
  6. Biologic therapies in pediatric psoriasis: A single-center experience. Archivos argentinos de pediatria · 30 Jun 2026 PMID 42377011
  7. Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025). Journal of managed care & specialty pharmacy · 24 Jun 2026 PMID 42341073
  8. Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: A Clinical Experience. Saudi medical journal · 15 Jun 2026 PMID 42293717
  9. Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database. Proceedings (Baylor University. Medical Center) · 10 Jun 2026 PMID 42269048
  10. The Longer-Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population-Based Study. Pharmacoepidemiology and drug safety · 20 May 2026 PMID 42157439
Human data, design not indexed (3)
  1. Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
  2. Methotrexate's effect on cells and adalimumab immunogenicity in axial spondyloarthritis: A mathematical study. PLoS computational biology · 21 Sept 2026 PMID 42766629
  3. Position-dependent effects of loop proline residues on Fab stability and aggregation. Biochemical and biophysical research communications · 21 Jul 2026 PMID 42480179
Preclinical: animal, cell and lab studies (3)
  1. Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies. Science advances · 2 Oct 2026 PMID 42826187
  2. Adalimumab-polyelectrolyte nanocomplexes decelerate synovial drug clearance ex vivo. Nanoscale · 16 Jun 2026 PMID 42300546
  3. Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt-Koyanagi-Harada Syndrome. Investigative ophthalmology & visual science · 2 Jun 2026 PMID 42227805
Unclassified: not yet indexed with MeSH (3)
  1. Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization. Revista espanola de enfermedades digestivas · 26 Oct 2026 PMID 42929266
  2. Efficacy and safety of adalimumab as first-line therapy for treatment-naïve granulomatous lobular mastitis: an exploratory real-world study with propensity score-matching analysis. Clinical rheumatology · 26 Sept 2026 PMID 42799973
  3. Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183